Noradrenaline Sintetica (Noradrenaline Tartrate)

Noradrenaline Tartrate stimulates α1‑adrenergic receptors, causing peripheral vasoconstriction that increases systemic vascular resistance. At the same time it activates β1‑adrenergic receptors in the heart, enhancing contractility and heart rate. The combined effect raises arterial pressure and cardiac output, stabilising haemodynamics.

The infusion rate of Noradrenaline Sintetica is individualized by the prescribing clinician. Dosage is titrated to the patient’s blood‑pressure response, usually starting at a low microgram‑per‑kilogram‑per‑minute range and adjusted until the desired haemodynamic target is achieved.

Pregnancy and lactation categories for Noradrenaline Tartrate are not well defined. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Noradrenaline primarily provides strong α‑adrenergic vasoconstriction with modest β1 activity, making it effective for raising systemic vascular resistance while supporting cardiac output. Dopamine has dose‑dependent effects, offering renal vasodilation at low doses and stronger β1 stimulation at moderate doses, but may cause more tachyarrhythmias. Choice depends on the clinical scenario and physician judgment.

Noradrenaline Sintetica must be stored at 2‑8 °C, protected from light, and kept in its original packaging. It should not be frozen or shaken. Before use, inspect the solution for particulate matter and ensure proper aseptic technique during preparation and infusion.

The product is given as an intravenous infusion. It is typically diluted in a compatible carrier solution (e.g., 5% dextrose or normal saline) and administered via a calibrated infusion pump. Continuous haemodynamic monitoring is required, and the infusion rate is adjusted according to the patient’s response.

Serious risks include myocardial ischemia, severe hypertension, and tissue necrosis at the infusion site due to extravasation. These events can be life‑threatening and require immediate medical intervention, such as stopping the infusion, providing supportive therapy, and treating any local tissue injury.

Noradrenaline is contraindicated in patients with known pheochromocytoma, untreated hypovolemia, or severe peripheral vascular disease where further vasoconstriction could cause tissue loss. Caution is also advised in individuals taking MAO inhibitors or certain antidepressants due to the risk of hypertensive crises.